BACKGROUND: Chronic opioid therapy has increased dramatically, as have complications related to prescription opioids. Little is known about the problems and concerns attributed to opioids by patients receiving different opioid doses. METHODS: We surveyed 1883 patients who were receiving chronic opioid therapy for chronic noncancer pain. Opioid regimen characteristics were ascertained from electronic pharmacy records. Patient-reported opioid-related problems and concerns were measured using the Prescription Opioid Difficulties Scale. Depression was assessed with the Patient Health Questionnaire. RESULTS: Patients prescribed higher opioid doses reported modestly higher pain intensity and pain impact. After adjustment, patients on higher doses attributed higher levels of psychosocial problems and control concerns to prescribed opioids (P<.0001). They also had higher levels of depression and were more likely to meet criteria for clinical depression. Over 60% of patients receiving 120+ mg daily (morphine equivalent) were clinically depressed, a 2.6-fold higher risk (95% confidence interval: 1.5-4.4) than patients on low-dose regimens (<20 mg daily). CONCLUSIONS: Higher opioid doses were associated with somewhat higher pain severity and higher levels of patient-reported opioid-related psychosocial problems, control concerns and depression. These findings may result from patient selection for high-dose therapy or problems caused by higher-dose opioids.
BACKGROUND: Chronic opioid therapy has increased dramatically, as have complications related to prescription opioids. Little is known about the problems and concerns attributed to opioids by patients receiving different opioid doses. METHODS: We surveyed 1883 patients who were receiving chronic opioid therapy for chronic noncancer pain. Opioid regimen characteristics were ascertained from electronic pharmacy records. Patient-reported opioid-related problems and concerns were measured using the Prescription Opioid Difficulties Scale. Depression was assessed with the Patient Health Questionnaire. RESULTS:Patients prescribed higher opioid doses reported modestly higher pain intensity and pain impact. After adjustment, patients on higher doses attributed higher levels of psychosocial problems and control concerns to prescribed opioids (P<.0001). They also had higher levels of depression and were more likely to meet criteria for clinical depression. Over 60% of patients receiving 120+ mg daily (morphine equivalent) were clinically depressed, a 2.6-fold higher risk (95% confidence interval: 1.5-4.4) than patients on low-dose regimens (<20 mg daily). CONCLUSIONS: Higher opioid doses were associated with somewhat higher pain severity and higher levels of patient-reported opioid-related psychosocial problems, control concerns and depression. These findings may result from patient selection for high-dose therapy or problems caused by higher-dose opioids.
Authors: Stephen F Butler; Simon H Budman; Kathrine C Fernandez; Brian Houle; Christine Benoit; Nathaniel Katz; Robert N Jamison Journal: Pain Date: 2007-05-09 Impact factor: 6.961
Authors: Meredith Noble; Jonathan R Treadwell; Stephen J Tregear; Vivian H Coates; Philip J Wiffen; Clarisse Akafomo; Karen M Schoelles Journal: Cochrane Database Syst Rev Date: 2010-01-20
Authors: Jeffrey F Scherrer; Joanne Salas; Laurel A Copeland; Eileen M Stock; Brian K Ahmedani; Mark D Sullivan; Thomas Burroughs; F David Schneider; Kathleen K Bucholz; Patrick J Lustman Journal: Ann Fam Med Date: 2016 Jan-Feb Impact factor: 5.166
Authors: C Patrick Carroll; Sophie Lanzkron; Carlton Haywood; Kasey Kiley; Megan Pejsa; Gyasi Moscou-Jackson; Jennifer A Haythornthwaite; Claudia M Campbell Journal: Am J Prev Med Date: 2016-07 Impact factor: 5.043
Authors: John A Sturgeon; Jennifer M Hah; Yasamin Sharifzadeh; Stephanie K Middleton; Thomas Rico; Kevin A Johnson; Sean C Mackey Journal: Int J Behav Med Date: 2018-04
Authors: Stephen W Patrick; Judith Dudley; Peter R Martin; Frank E Harrell; Michael D Warren; Katherine E Hartmann; E Wesley Ely; Carlos G Grijalva; William O Cooper Journal: Pediatrics Date: 2015-04-13 Impact factor: 7.124
Authors: A Carmona-Bayonas; P Jiménez-Fonseca; E Castañón; A Ramchandani-Vaswani; R Sánchez-Bayona; A Custodio; D Calvo-Temprano; J A Virizuela Journal: Clin Transl Oncol Date: 2016-07-21 Impact factor: 3.405